Payment overview · 2025
General Payments
$923.73
47 reported records · 14 companies
Healthcare provider profile · identity verified
Patrick Ratnasamy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEMOYNE, PA · NPI 1063403475
Verified facts
What the public records show
CMS Open Payments records show Patrick Ratnasamy, MD received $923.73 in general payments during 2025 across 47 reported records.
ABBVIE INC. accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $235.38 | 25.5% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $166.16 | 18.0% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $122.95 | 13.3% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $69.73 | 7.5% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $61.54 | 6.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.28 | 4.8% | 3 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $41.16 | 4.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $37.25 | 4.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.10 | 3.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.08 | 3.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.45 | 3.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.23 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.10 | 1.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.32 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $879.23 | 46 |
| Education | $44.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $140.97 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $94.41 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.36 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $78.00 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $77.40 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $73.18 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.99 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.99 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $69.73 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $61.54 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.55 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.28 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.28 | 3 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $41.16 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $41.16 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $41.16 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.08 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.45 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 112 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 470 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 264 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 41 |
| Lisinopril | Lisinopril | 148 | 49 |
| Furosemide | Furosemide | 147 | 47 |
| Gabapentin | Gabapentin | 143 | 38 |
| Prednisone | Prednisone | 142 | 101 |
| Losartan Potassium | Losartan Potassium | 132 | 38 |
| Metformin Hcl Er | Metformin Hcl | 121 | 38 |
| Potassium Chloride | Potassium Chloride | 117 | 31 |
| Eliquis | Apixaban | 112 | 23 |
| Omeprazole | Omeprazole | 112 | 33 |
| Allopurinol | Allopurinol | 104 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 22 |
| Metformin Hcl | Metformin Hcl | 97 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 34 |
| Sertraline Hcl | Sertraline Hcl | 90 | 19 |
| Lorazepam | Lorazepam | 89 | 41 |
| Tramadol Hcl | Tramadol Hcl | 89 | 41 |
| Finasteride | Finasteride | 87 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 23 |
| Azithromycin | Azithromycin | 70 | 57 |
| Trazodone Hcl | Trazodone Hcl | 70 | 27 |
| Xarelto | Rivaroxaban | 70 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 60 |
| Glimepiride | Glimepiride | 66 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 65 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 17 |
| Mounjaro | Tirzepatide | 61 | 11 |
| Meloxicam | Meloxicam | 60 | 29 |
| Simvastatin | Simvastatin | 59 | 17 |
| Bumetanide | Bumetanide | 58 | 17 |
| Donepezil Hcl | Donepezil Hcl | 57 | 11 |
| Jardiance | Empagliflozin | 57 | 17 |
| Montelukast Sodium | Montelukast Sodium | 57 | 21 |
| Cefuroxime | Cefuroxime Axetil | 53 | 43 |
| Famotidine | Famotidine | 53 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 14 |
| Bupropion Xl | Bupropion Hcl | 51 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 17 |
| Ozempic | Semaglutide | 50 | 13 |
| Alendronate Sodium | Alendronate Sodium | 48 | 15 |
| Fenofibrate | Fenofibrate | 47 | 13 |
| Synthroid | Levothyroxine Sodium | 45 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 15 |
| Warfarin Sodium | Warfarin Sodium | 43 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 14 |
| Ezetimibe | Ezetimibe | 41 | 16 |
| Methylprednisolone | Methylprednisolone | 41 | 38 |
| Atenolol | Atenolol | 40 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 25 |
| Brilinta | Ticagrelor | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 23 |
| Carvedilol | Carvedilol | 36 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 11 |
| Cephalexin | Cephalexin | 31 | 30 |
| Meclizine Hcl | Meclizine Hcl | 31 | 20 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 13 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 17 |
| Valsartan | Valsartan | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 19 |
| Tradjenta | Linagliptin | 21 | suppressed |
| Erythromycin | Erythromycin Base | 20 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Ofloxacin | Ofloxacin | 20 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | 11 |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 13 |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Nicardipine Hcl | Nicardipine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Desonide | Desonide | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $923.73 · 47 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, CAMZYOS, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, Flector, GEMTESA, Licart, NEXLETOL, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Tirosint, UBRELVY, VRAYLAR, Wegovy, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error